Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening ...
While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...
Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call ...
The FDA has cleared BeOne Medicines’ BCL2 blocker sonrotoclax for the treatment of certain patients with mantle cell lymphoma ...
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa ...
Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...
In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to ...
After a 12-month period that saw the Belgian biotech consider a spinout, swap out CEOs, and enter a three-way acquisition ...
Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by ...
The FDA's decision last year to make complete response letters public provides new insight into why therapies sometimes fail ...
Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.
The widely covered impending ouster of FDA Commissioner Marty Makary not long after the exit of controversial biologics head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results